Mineralys Therapeutics, Inc. MLYS Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s common stock, shares authorized (in shares)?
- Mineralys Therapeutics, Inc. (MLYS) reported common stock, shares authorized (in shares) of $500M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- Mineralys Therapeutics, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $500M to $500M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s common stock, shares authorized (in shares)?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s common stock, shares authorized (in shares) has grown at a 16.2% compound annual growth rate (CAGR), from $319M to $500M.